154 related articles for article (PubMed ID: 35871080)
21. Recurrent KRAS, KIT and SF3B1 mutations in melanoma of the female genital tract.
Cai YJ; Ke LF; Zhang WW; Lu JP; Chen YP
BMC Cancer; 2021 Jun; 21(1):677. PubMed ID: 34102999
[TBL] [Abstract][Full Text] [Related]
22. The genetic landscape of ganglioglioma.
Pekmezci M; Villanueva-Meyer JE; Goode B; Van Ziffle J; Onodera C; Grenert JP; Bastian BC; Chamyan G; Maher OM; Khatib Z; Kleinschmidt-DeMasters BK; Samuel D; Mueller S; Banerjee A; Clarke JL; Cooney T; Torkildson J; Gupta N; Theodosopoulos P; Chang EF; Berger M; Bollen AW; Perry A; Tihan T; Solomon DA
Acta Neuropathol Commun; 2018 Jun; 6(1):47. PubMed ID: 29880043
[TBL] [Abstract][Full Text] [Related]
23. MSI-High RAS-BRAF wild-type colorectal adenocarcinomas with MLH1 loss have a high frequency of targetable oncogenic gene fusions whose diagnoses are feasible using methods easy-to-implement in pathology laboratories.
Bocciarelli C; Caumont C; Samaison L; Cariou M; Aline-Fardin A; Doucet L; Roudié J; Terris B; Merlio JP; Marcorelles P; Cappellen D; Uguen A
Hum Pathol; 2021 Aug; 114():99-109. PubMed ID: 34019865
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and Safety of Trametinib in Non-V600 BRAF Mutant Melanoma: A Phase II Study.
Nebhan CA; Johnson DB; Sullivan RJ; Amaria RN; Flaherty KT; Sosman JA; Davies MA
Oncologist; 2021 Sep; 26(9):731-e1498. PubMed ID: 33861486
[TBL] [Abstract][Full Text] [Related]
25. Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma.
Greaves WO; Verma S; Patel KP; Davies MA; Barkoh BA; Galbincea JM; Yao H; Lazar AJ; Aldape KD; Medeiros LJ; Luthra R
J Mol Diagn; 2013 Mar; 15(2):220-6. PubMed ID: 23273605
[TBL] [Abstract][Full Text] [Related]
26. Frequent CD30 Expression in an Emerging Group of Mesenchymal Tumors With NTRK, BRAF, RAF1, or RET Fusions.
Kojima N; Mori T; Motoi T; Kobayashi E; Yoshida M; Yatabe Y; Ichikawa H; Kawai A; Yonemori K; Antonescu CR; Yoshida A
Mod Pathol; 2023 Apr; 36(4):100083. PubMed ID: 36788089
[TBL] [Abstract][Full Text] [Related]
27. Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas.
Griewank KG; Westekemper H; Murali R; Mach M; Schilling B; Wiesner T; Schimming T; Livingstone E; Sucker A; Grabellus F; Metz C; Süsskind D; Hillen U; Speicher MR; Woodman SE; Steuhl KP; Schadendorf D
Clin Cancer Res; 2013 Jun; 19(12):3143-52. PubMed ID: 23633454
[TBL] [Abstract][Full Text] [Related]
28. Clinical and genetic analysis of melanomas arising in acral sites.
Zaremba A; Murali R; Jansen P; Möller I; Sucker A; Paschen A; Zimmer L; Livingstone E; Brinker TJ; Hadaschik E; Franklin C; Roesch A; Ugurel S; Schadendorf D; Griewank KG; Cosgarea I
Eur J Cancer; 2019 Sep; 119():66-76. PubMed ID: 31419753
[TBL] [Abstract][Full Text] [Related]
29. Transcriptional Profiling of Malignant Melanoma Reveals Novel and Potentially Targetable Gene Fusions.
Darabi S; Elliott A; Braxton DR; Zeng J; Hodges K; Poorman K; Swensen J; Shanthappa BU; Hinton JP; Gibney GT; Moser J; Phung T; Atkins MB; In GK; Korn WM; Eisenberg BL; Demeure MJ
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326655
[TBL] [Abstract][Full Text] [Related]
30. Molecular Pathology of Anaplastic Thyroid Carcinomas: A Retrospective Study of 144 Cases.
Bonhomme B; Godbert Y; Perot G; Al Ghuzlan A; Bardet S; Belleannée G; Crinière L; Do Cao C; Fouilloux G; Guyetant S; Kelly A; Leboulleux S; Buffet C; Leteurtre E; Michels JJ; Tissier F; Toubert ME; Wassef M; Pinard C; Hostein I; Soubeyran I
Thyroid; 2017 May; 27(5):682-692. PubMed ID: 28351340
[TBL] [Abstract][Full Text] [Related]
31. NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors.
Thielmann CM; Chorti E; Matull J; Murali R; Zaremba A; Lodde G; Jansen P; Richter L; Kretz J; Möller I; Sucker A; Herbst R; Terheyden P; Utikal J; Pföhler C; Ulrich J; Kreuter A; Mohr P; Gutzmer R; Meier F; Dippel E; Weichenthal M; Paschen A; Livingstone E; Zimmer L; Schadendorf D; Hadaschik E; Ugurel S; Griewank KG
Eur J Cancer; 2021 Dec; 159():113-124. PubMed ID: 34742158
[TBL] [Abstract][Full Text] [Related]
32. Mutational analysis using next generation sequencing in pediatric thyroid cancer reveals BRAF and fusion oncogenes are common.
Newfield RS; Jiang W; Sugganth DX; Hantash FM; Lee E; Newbury RO
Int J Pediatr Otorhinolaryngol; 2022 Jun; 157():111121. PubMed ID: 35397361
[TBL] [Abstract][Full Text] [Related]
33. Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation.
Bae JS; Kim Y; Jeon S; Kim SH; Kim TJ; Lee S; Kim MH; Lim DJ; Lee YS; Jung CK
Diagn Pathol; 2016 Feb; 11():21. PubMed ID: 26857243
[TBL] [Abstract][Full Text] [Related]
34. ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.
Aisner DL; Nguyen TT; Paskulin DD; Le AT; Haney J; Schulte N; Chionh F; Hardingham J; Mariadason J; Tebbutt N; Doebele RC; Weickhardt AJ; Varella-Garcia M
Mol Cancer Res; 2014 Jan; 12(1):111-8. PubMed ID: 24296758
[TBL] [Abstract][Full Text] [Related]
35. Clinical response under MEK inhibitor alone in metastatic melanoma with a novel fusion involving the RAF1 gene.
Boileau M; Descarpentries C; Delzenne G; Trentesaux V; Greliak A; Jamme P; Marchetti P; Mortier L
Melanoma Res; 2023 Jun; 33(3):247-251. PubMed ID: 36866640
[TBL] [Abstract][Full Text] [Related]
36. Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions.
Cocco E; Benhamida J; Middha S; Zehir A; Mullaney K; Shia J; Yaeger R; Zhang L; Wong D; Villafania L; Nafa K; Scaltriti M; Drilon A; Saltz L; Schram AM; Stadler ZK; Hyman DM; Benayed R; Ladanyi M; Hechtman JF
Cancer Res; 2019 Mar; 79(6):1047-1053. PubMed ID: 30643016
[TBL] [Abstract][Full Text] [Related]
37. Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement.
Antonescu CR; Suurmeijer AJ; Zhang L; Sung YS; Jungbluth AA; Travis WD; Al-Ahmadie H; Fletcher CD; Alaggio R
Am J Surg Pathol; 2015 Jul; 39(7):957-67. PubMed ID: 25723109
[TBL] [Abstract][Full Text] [Related]
38. A primary melanoma and its asynchronous metastasis highlight the role of BRAF, CDKN2A, and TERT.
Hosler GA; Davoli T; Mender I; Litzner B; Choi J; Kapur P; Shay JW; Wang RC
J Cutan Pathol; 2015 Feb; 42(2):108-17. PubMed ID: 25407517
[TBL] [Abstract][Full Text] [Related]
39. Activation of mutant TERT promoter by RAS-ERK signaling is a key step in malignant progression of BRAF-mutant human melanomas.
Li Y; Cheng HS; Chng WJ; Tergaonkar V
Proc Natl Acad Sci U S A; 2016 Dec; 113(50):14402-14407. PubMed ID: 27911794
[TBL] [Abstract][Full Text] [Related]
40. Highly Concordant Key Genetic Alterations in Primary Tumors and Matched Distant Metastases in Differentiated Thyroid Cancer.
Sohn SY; Park WY; Shin HT; Bae JS; Ki CS; Oh YL; Kim SW; Chung JH
Thyroid; 2016 May; 26(5):672-82. PubMed ID: 26971368
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
